|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AA28
|
|
gptkbp:CASNumber
|
1147702-22-4
|
|
gptkbp:contains
|
human IgG1 Fc region
modified CTLA-4 domain
|
|
gptkbp:contraindication
|
EBV seronegative patients
|
|
gptkbp:drugClass
|
gptkb:immunosuppressant
|
|
gptkbp:form
|
lyophilized powder for solution
|
|
gptkbp:genericName
|
gptkb:belatacept
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:mechanismOfAction
|
selective T-cell costimulation blocker
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:riskFactor
|
increased risk of infection
post-transplant lymphoproliferative disorder
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
diarrhea
urinary tract infection
cough
peripheral edema
|
|
gptkbp:target
|
gptkb:CD80
gptkb:CD86
|
|
gptkbp:UNII
|
Q1P0P0JZ5N
|
|
gptkbp:usedFor
|
prevention of organ rejection
|
|
gptkbp:usedIn
|
kidney transplantation
|
|
gptkbp:bfsParent
|
gptkb:belatacept
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nulojix
|